MOTS-c Peptide: What the Evidence Shows, and What FDA Found

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, and its reputation as a weight-loss and “exercise in a vial” peptide rests on mouse studies. In mice fed a high-fat diet, daily injections slowed weight gain and improved insulin sensitivity.^[6] No published trial has given MOTS-c to people: when FDA reviewed it in 2026, it found no clinical studies and no human exposure data by any route.^[1] The only human drug data come from CB4211, a modified version tested for four weeks by a company that has since wound down. There is no established human dose. MOTS-c is not approved, not on the list of ingredients US pharmacies may compound with, and is banned in sport.

What MOTS-c is

Almost every protein in the body is encoded in the DNA of the cell nucleus. Mitochondria, the structures that turn food into usable energy, carry a small genome of their own, and in 2015 a team at the University of Southern California reported that a short stretch of it, inside the gene for a mitochondrial RNA called 12S rRNA, codes for a 16-amino-acid peptide. They named it MOTS-c, for mitochondrial open reading frame of the 12S rRNA-c.^[6] It circulates in the blood of both people and rodents.^[1]

In cells, MOTS-c appears to act mainly on skeletal muscle and to switch on AMPK, an energy sensor that also responds to exercise and to the diabetes drug metformin.^[6] A 2018 follow-up reported that under metabolic stress MOTS-c moves into the nucleus and changes the activity of genes involved in stress and antioxidant defense.^[7] That is how it came to be sold as an “exercise mimetic.” FDA’s 2026 review adds a caution: the molecular target that MOTS-c binds to “remains unknown,” which makes it hard to predict which organs it would affect.^[1]

One more detail matters for anyone reading the research. Several of the founding papers were written by scientists who disclosed that they were consultants and shareholders of CohBar, the company set up to turn mitochondrial peptides into drugs.^[7][8][10] That does not make the findings wrong. It does mean most of the early work came from one circle of researchers with a commercial stake, and independent replication is thin.

The MOTS-c evidence, sorted by what was actually studied

The mouse data: real, consistent, and still mice

The 2015 paper is the one every seller cites. Mice fed a diet that was 60% fat and given daily MOTS-c injections for eight weeks gained less weight than untreated mice on the same diet and ended about 20% lighter, with less fat in the liver and lower insulin levels. In a separate test, older mice treated for a week regained the muscle insulin sensitivity of young mice.^[6][1] Later studies from the same group and others found similar effects in obese mice and in mice that had their ovaries removed.^[8][9]

The 2021 study widened the claim to aging. Mice of every age ran longer on a treadmill after a dose of MOTS-c, and mice that started treatment very late in life, three times a week, stayed fitter and lived somewhat longer: a median of 970 days against 912 for untreated mice.^[10][1]

FDA’s reviewers summarized the limits plainly. Every one of these studies was in rodents or rodent cells, none tested how the effect changes with dose, and the doses were mostly injected into the abdominal cavity rather than under the skin, the route the nominating pharmacy proposed.^[1] A 2023 review that is broadly enthusiastic about MOTS-c still concludes that “no effective method of applying MOTS-c in the clinic has been developed.”^[14] Results in mouse metabolism studies often fail to carry over to people, which is why a drug needs human trials before anyone can say it works.

What the human studies actually measured

There are human MOTS-c studies, and sellers often cite them as though they tested the peptide as a treatment. They did not. They measured the MOTS-c a person’s own body makes, in blood or muscle, before and after exercise.

• One exercise session. In a Swedish study, 30 adults were randomized to 45 minutes of cycling, a leg-weights session, or rest. A related peptide, humanin, rose after cycling. MOTS-c only showed a trend toward rising, and blood levels of either peptide were unrelated to how fit people were.^[11]
• Sixteen weeks of training. In breast cancer survivors randomized to exercise or usual care, blood MOTS-c rose with training in non-Hispanic White women but not in Hispanic women.^[12]
• The Nature Communications paper reported that exercise raised MOTS-c in human muscle and blood, alongside its mouse experiments.^[10]

Even the measurement is shaky. Anti-doping scientists in Cologne who built a precise mass-spectrometry test for MOTS-c could not confirm the blood levels that a commercial antibody kit reported in healthy people, and found “considerable differences” between the two methods.^[13] Many of the human studies rely on that kind of kit. Their finding that exercise nudges MOTS-c upward says nothing about whether injecting extra MOTS-c does anything.

FDA searched PubMed, Embase, the Cochrane database and ClinicalTrials.gov in its review. Its conclusion: it “did not identify data, such as clinical studies, evaluating the administration of MOTS-c to humans.”^[1] The pharmacy that nominated MOTS-c cited 12 papers, and none was a clinical study.^[1]

CB4211: the one human drug test, and what happened to it

The nearest thing to a human MOTS-c trial used a different molecule. CohBar, the California company co-founded around this research, developed CB4211, which it described as “a novel and improved analog of MOTS-c.”^[16] It ran a phase 1a/1b study registered on ClinicalTrials.gov that enrolled 88 people and finished in April 2021.^[15]

According to the company’s announcement, the first part tested single and repeated doses in 65 healthy adults. The second part gave 25 mg of CB4211 by daily injection under the skin for four weeks to 20 adults with obesity and fatty liver disease, 11 on the drug and 9 on placebo.^[16] The company reported:

• Liver enzymes fell. ALT dropped 21% from baseline on CB4211, a 25-point difference from placebo; AST dropped 28% against 11% on placebo.
• Glucose fell slightly: 6% on CB4211, no change on placebo.
• Weight: only “a trend towards lower body weight.” No weight figure was given in the release. Liver fat fell substantially in both groups, including placebo.
• Side effects: no serious adverse events; the only side effect in more than 10% of people on the drug was mild to moderate injection-site reactions.

Those results are company-reported. The ClinicalTrials.gov record has no results posted,^[15] and a PubMed search for CB4211 finds no published paper. Four weeks in 11 people cannot show whether a drug causes weight loss. And CB4211 is not MOTS-c, so even good results would not tell you what the sold peptide does.

CohBar never ran a larger trial. In November 2023 its planned merger with another biotech collapsed after Nasdaq signaled it would not approve the listing, and CohBar said it “intends to commence the process of liquidating and dissolving itself.”^[17] Weeks later Nasdaq judged it a “public shell” and its shares were suspended from trading.^[18] The only company that took a MOTS-c-type drug into people left the field without publishing the data.

One new trial is listed, and it should be read with caution. A registry entry from a sponsor called Hudson Biotech describes a phase 2a study in Shenzhen, China, randomizing 120 adults with prediabetes and overweight to daily MOTS-c injections or placebo for 12 weeks, with insulin sensitivity as the main outcome and no dose stated.^[19] The same sponsor’s TB-500 entry on the same registry opens by calling itself “fictional,” so neither listing can be taken at face value. A registry listing is not evidence either way, and there is still no human efficacy data for MOTS-c.

MOTS-c dosage: what sellers claim and what was actually tested

There is no established human dose of MOTS-c. No study has given it to people and measured what different doses do, so every dose on a vendor site, clinic protocol or forum is a guess. Online protocols disagree widely, from fractions of a milligram several times a week to 5 mg or more at a time. None of them traces back to a human study.

There is a further problem with injected MOTS-c that dose charts ignore. In a lab test, MOTS-c added to human blood broke down into fragments quickly.^[1][13] FDA found no study measuring how long injected MOTS-c lasts in the body, and said it “remains to be determined” whether giving it to people can reach active levels at all.^[1] Mouse doses per kilogram also cannot simply be scaled up to a person. We do not publish a dosing protocol, because printing one would suggest a validated regimen exists.

Side effects and safety: unknown, not proven safe

Nobody has measured MOTS-c’s side effects in people, because nobody has run the study. FDA found no toxicity studies of any kind: no single-dose, repeat-dose or genetic toxicity tests.^[1] Its safety-risk page says:

“FDA has not identified any human exposure data on drug products containing MOTs-C administered via any route of administration. FDA lacks important information regarding any safety issues raised by MOTs-C, including whether it would cause harm if administered to humans.”^[2]

— FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks

• Immune reactions. Injected peptides can trigger antibodies, and impurities or clumping make that more likely. FDA said it cannot rule this out for MOTS-c.^[1][2]
• No adverse-event reports, which is not the same as safe. FDA’s adverse-event database held no MOTS-c reports through March 2025, but pharmacies compounding under 503A generally do not report to FDA.^[1]
• Which molecule is in the vial? MOTS-c has no official drug name, FDA has seen different salts and derivatives sold under it, and the nominating pharmacy’s paperwork did not make clear which form it meant.^[1]
• Blood sugar. MOTS-c lowered glucose in mice.^[8] What it does to blood sugar in a person taking a GLP-1, insulin or metformin has never been studied.

Is MOTS-c legal? FDA status and the July 2026 vote

A US pharmacy compounding under section 503A may only use an ingredient that has an official monograph, is part of an approved drug, or is on FDA’s 503A bulks list.^[4] MOTS-c has no monograph and is not in any approved drug.^[1] The bulks list currently names six substances, none of them a peptide.^[5] FDA’s safety-risk page lists MOTS-c among substances “nominated but withdrawn” from its Category 2, which does not give pharmacies any route to compound it.^[2]

FDA’s Pharmacy Compounding Advisory Committee considered MOTS-c for obesity and osteoporosis on July 23, 2026.^[3] FDA’s own scientists had written that “a balancing of the criteria weighs against” listing it.^[1] According to trade press, the committee voted 7 to 5, with two abstentions, to recommend it anyway.^[20][21] FDA’s meeting page posts no vote summary.^[3] The committee only advises: FDA is not bound by the vote, and adding a substance to the list takes notice-and-comment rulemaking.^[21] As of mid-October 2026 no such rule has been published.^[5]

Our peptide legal-status guide covers the other peptides on the same lists, and 503A vs 503B pharmacies explains the two compounding channels. KPV and BPC-157 went before the same committee the same day: see the KPV evidence and what FDA said about BPC-157.

MOTS-c and anti-doping rules

Athletes subject to drug testing should know that MOTS-c is named on the World Anti-Doping Agency’s 2026 Prohibited List, in the class of metabolic modulators that activate AMPK, alongside AICAR. That class is prohibited at all times, in and out of competition.^[22] A validated test for detecting synthetic MOTS-c in plasma was published in 2019 for doping control.^[13]

“Research use only” MOTS-c: what that label means

Much of the MOTS-c sold online comes in vials marked “not for human consumption” or “for research use only.” The label does not change what the product is if it is sold for people to inject. In a December 2024 warning letter to a research-peptide seller, FDA said that despite “RESEARCH USE ONLY” labels, evidence from the seller’s websites showed the products were “intended to be drugs for human use,” and so were unapproved drugs.^[23] That letter concerned GLP-1 products, but the reasoning is general.

For a buyer, a research label means no prescriber has checked the product suits you, no licensed pharmacy made it, no drug-quality manufacturing rules applied, and the certificate of analysis comes from the seller. With a peptide FDA says is sold in several different chemical forms under one name, that last point matters.^[1] The same issues with research-labeled GLP-1s are covered in buying tirzepatide as a research chemical.

MOTS-c also appears on prescription peptide menus. Of the 153 telehealth sellers in our register with a structured peptide menu, five list MOTS-c. A prescriber adds oversight that a research-chemical site does not, but it does not create evidence. Whoever writes the prescription, there is still no human trial in which MOTS-c produced weight loss.

How MOTS-c compares with the approved GLP-1 drugs

The gap is not close. In STEP 1, 1,961 adults on weekly semaglutide 2.4 mg lost 14.9% of their body weight over 68 weeks, against 2.4% on placebo.^[24] In SURMOUNT-1, 2,539 adults on the top dose of tirzepatide lost 20.9% over 72 weeks, against 3.1% on placebo.^[25] Both drugs have FDA-approved labels built on those trials. MOTS-c has no human weight data at all; its closest relative managed a “trend” over four weeks in 11 people.^[16]

Our peptide menu review counts the human trials behind each peptide clinics sell beside GLP-1s, and MOTS-c is near the bottom. Another mitochondria-targeted peptide, elamipretide, did reach phase 3 and shows how hard the step to human benefit is: see elamipretide’s phase 3 that missed. For a growth-hormone fragment that was sold for fat loss and failed its human trials, see AOD-9604.